Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.38.

A number of equities research analysts have issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday. Piper Sandler started coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Guggenheim began coverage on Compass Therapeutics in a research report on Monday, February 24th. They set a “buy” rating and a $12.00 price target for the company. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $2.24 on Wednesday. The business has a 50-day moving average of $2.83 and a 200 day moving average of $2.11. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The stock has a market capitalization of $309.75 million, a PE ratio of -6.05 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Trading of Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Intech Investment Management LLC purchased a new stake in shares of Compass Therapeutics in the 3rd quarter worth approximately $30,000. Tower Research Capital LLC TRC boosted its holdings in Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after acquiring an additional 12,917 shares in the last quarter. Independent Advisor Alliance purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth $26,000. BNP Paribas Financial Markets bought a new position in shares of Compass Therapeutics during the fourth quarter valued at $27,000. Finally, XTX Topco Ltd bought a new position in shares of Compass Therapeutics during the third quarter valued at $37,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.